Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 1 of 1 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/15/22
End: 04/30/26
Due: 04/30/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| NP-101 (TQ Formula) with Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas | NCT05262556 | Amr Mohamed MD | user2@example.com | None | 2022-12-15 | 2026-04-30 | 2027-04-30 | - | - | 2025-07-14 |